IFNB1 and COVID-19: However, a large randomized controlled trial (RCT) did not demonstrate that the combination therapy of IFN-β and remdesivir can lead to reduce the time to clinical recovery, compared to remdesivir alone in hospitalized patients with moderate-to-severe COVID-19 [17].